Alkermes to Unveil Key Sleep Disorder Data at SLEEP 2026
Event summary
- Alkermes to present 26 abstracts at SLEEP 2026, including data on alixorexton and LUMRYZ.
- Vibrance-2 study results for alixorexton in narcolepsy type 2 to be shared in oral presentation.
- Company acquired Avadel Pharmaceuticals in February 2026, adding LUMRYZ to its sleep portfolio.
- Phase 3 REVITALYZ study data on LUMRYZ for idiopathic hypersomnia to be presented.
- Alixorexton has received Breakthrough Therapy designation from FDA for narcolepsy type 1.
The big picture
Alkermes is positioning itself as a leader in sleep medicine through its expanding portfolio of treatments for narcolepsy and idiopathic hypersomnia. The company's focus on orexin-based therapies and once-nightly formulations aligns with industry trends toward more convenient and targeted treatments for sleep disorders. The acquisition of Avadel Pharmaceuticals bolsters Alkermes' commercial capabilities in this growing therapeutic area.
What we're watching
- Clinical Efficacy
- Whether alixorexton's phase 2 results will translate to successful phase 3 outcomes in narcolepsy type 1 and 2.
- Regulatory Pathway
- The pace at which the FDA will review alixorexton given its Breakthrough Therapy designation.
- Market Positioning
- How Alkermes will differentiate LUMRYZ in the competitive sleep disorder market post-acquisition.